2022 Fiscal Year Final Research Report
Development of DHMEQ, a new drug that potently suppresses multiple inflammatory cytokines, for the treatment of SLE.
Project/Area Number |
19K17379
|
Research Category |
Grant-in-Aid for Early-Career Scientists
|
Allocation Type | Multi-year Fund |
Review Section |
Basic Section 52050:Embryonic medicine and pediatrics-related
|
Research Institution | Kansai Medical University |
Principal Investigator |
|
Project Period (FY) |
2019-04-01 – 2023-03-31
|
Keywords | SLE / サイトカイン / DHMEQ |
Outline of Final Research Achievements |
In a mouse model of systemic lupus erythematosus (SLE), dehydroxymethylepoxyquinomicin (DHMEQ) treatment predicted better survival than non-treated mice. The DHMEQ-treated group tended to have less proteinuria than the non-treated group, but this difference was not significant. Similar results were obtained despite adjustments in dosage and dosing interval.
|
Free Research Field |
自己免疫性疾患
|
Academic Significance and Societal Importance of the Research Achievements |
SLEモデルマウスにおいて、DHMEQ投与群が非投与群と比較して、生存率やタンパク尿等で有意差を認めなかった。DHMEQ以外にもNF-κB阻害剤は多数あり、今回の研究結果でNF-κB阻害剤のSLEモデルマウスに対する効果が否定されたわけではない。SLEの病態を考慮すると、サイトカインを抑制する治療に関する研究は、今後も検討していく必要があると考えられた。
|